Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys

Nature

Volumn 503, Issue 7475, 2013, Pages 224-228

  Barouch, Dan H ^a,b   Whitney, James B ^a   Moldt, Brian ^c   Klein, Florian ^d   Oliveira, Thiago Y ^d   Liu, Jinyan ^a   Stephenson, Kathryn E ^a   Chang, Hui Wen ^a   Shekhar, Karthik ^b   Gupta, Sanjana ^b   Nkolola, Joseph P ^a   Seaman, Michael S ^a   Smith, Kaitlin M ^a   Borducchi, Erica N ^a   Cabral, Crystal ^a   Smith, Jeffrey Y ^a   Blackmore, Stephen ^a   Sanisetty, Srisowmya ^a   Perry, James R ^a   Beck, Matthew ^a   Lewis, Mark G ^e   Rinaldi, William ^f   Chakraborty, Arup K ^b   Poignard, Pascal ^c   Nussenzweig, Michel C ^d,g   Burton, Dennis R ^b,c   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e BIOQUAL INC   (United States)

^f Alpha Genesis Inc   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIV 1 SPECIFIC MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS RNA; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; VIRUS DNA;

ANTIBODY; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM; PLASMA; RNA; SERUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL MUCOSA; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; LYMPH NODE; MALE; NONHUMAN; PRIORITY JOURNAL; REBOUND; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIREMIA; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; ANIMAL; BLOOD; IMMUNOLOGY; PHYSIOLOGY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; MUS; PRIMATES; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; DNA, VIRAL; HIV ANTIBODIES; HIV-1; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VIREMIA;

EID: 84887626950     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12744     Document Type: Article

References (39)

1. Burton, D. R., Poignard, P., Stanfield, R. L. & Wilson, I. A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337, 183-186 (2012).
2. Klein, F. et al. Antibodies in HIV-1 vaccine development and therapy. Science 341, 1199-1204 (2013).
3. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
4. Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817 (2010).
5. Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636-640 (2009).
6. Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
7. Diskin, R. et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334, 1289-1293 (2011).
8. Walker, L. M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
9. McLellan, J. S. et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343 (2011).
10. Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
11. Julien, J. P. et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4binding viarecognition of the HIV-1gp120V3 base and multiplesurrounding glycans. PLoS Pathog. 9, e1003342 (2013).
12. Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl Acad. Sci. USA 109, E3268-E3277 (2012).
13. Kong, L. et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nature Struct. Mol. Biol. 20, 796-803 (2013).
14. Huang, J. et al. Broad and potentneutralizationofHIV-1byagp41-specific human antibody. Nature 491, 406-412 (2012).
15. Poignard, P. et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10, 431-438 (1999).
16. Trkola, A. et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nature Med. 11, 615-622 (2005).
17. Mehandru, S. et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J. Virol. 81, 11016-11031 (2007).
18. Klein, F. et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118-122 (2012).
19. Diskin, R. et al. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J. Exp. Med. 210, 1235-1249 (2013).
20. Burton, D. R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027 (1994).
21. West, A. P. Jr et al. Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc. Natl Acad. Sci. USA 110, 10598-10603 (2013).
22. Montefiori, D. Evaluating Neutralizing Antibodies Against HIV, SIV and SHIV in Luciferase Reporter Gene Assays. Current Protocols Immunol (John Wiley & Sons, 2004).
23. Pitcher, C. J. et al. Development and homeostasis of T cell memory in rhesus macaque. J. Immunol. 168, 29-43 (2002).
24. Liu, J. et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82, 4844-4852 (2008).
25. Stephenson, K. E., Li, H., Walker, B. D., Michael, N. L. & Barouch, D. H. Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys. J. Virol. 86, 9583-9589 (2012).
26. Whitney, J. B. et al. T-cell vaccination reduces simian immunodeficiency virus levels in semen. J. Virol. 83, 10840-10843 (2009).
27. Li, H. et al. Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys. J. Virol. 85, 11007-11015 (2011).
28. Andrade, A. et al. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J. Infect. Dis. 208, 884-891 (2013).
29. Horwitz, J. A. et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl Acad. Sci. USA 110, 16538-16543 (2013).
30. Cornall, A. et al. A novel, rapid method to detect infectious HIV-1 from plasma of persons infected with HIV-1. J. Virol. Methods 165, 90-96 (2010).
31. Jaworski, J. P. et al. Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques. J. Virol. 87, 10447-10459 (2013).
32. Ng, C. T. et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nature Med. 16, 1117-1119 (2010).
33. Jayaraman, P. et al. Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3. J. Virol. 81, 822-834 (2007).
34. Kraft, Z. et al. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J. Virol. 81, 6402-6411 (2007).
35. Barouch, D. H. et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155, 531-539 (2013).
36. Barouch, D. H. et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482, 89-93 (2012).
37. Liu, J. et al. Immune controlof an SIV challenge by a T-cell-based vaccine inrhesus monkeys. Nature 457, 87-91 (2009).
38. Nishimura, Y. et al. Generation of the pathogenic R5-tropic simian/human immunodeficiencyvirusSHIVAD8byserialpassaginginrhesusmacaques. J. Virol. 84, 4769-4781 (2010).
39. Gautam, R. et al. Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. J. Virol. 86, 8516-8526 (2012).